New hope for cervical cancer? drug cocktail targets tumors that resist immunotherapy
NCT ID NCT07186868
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy, with or without a blood-vessel-blocking drug, in 25 women whose recurrent or metastatic cervical cancer has worsened after prior PD-1/PD-L1 treatment. The goal is to see how many patients' tumors shrink or disappear. All participants receive the same treatment, and researchers will monitor side effects and survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
iparomlimab and tuvonralimab (QL1706) plus nab-paclitaxel, with or without bevacizumab
What this could lead to
If successful, this could offer a new treatment option for women with cervical cancer that has stopped responding to standard immunotherapy.
What could go wrong
This is a very early, small study with only 25 participants and no comparison group. The combination may cause significant side effects, and results may not apply to broader populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.